Federal prosecutors have reached a $17 million settlement with Acadia after Medicaid fraud allegations; rates of heart failure–related deaths are on the rise among adults between 35 and 64 years old; the FDA has asked manufacturers of sunscreen to review the safety of the chemicals used in their products after a new study found that many of the ingredients in sunscreen may be absorbed into the bloodstream upon use.
Federal prosecutors have reached a $17 million settlement with the healthcare company Acadia, which was accused of Medicaid fraud in West Virginia, Associated Press reported. United States Attorney Mike Stuart said the healthcare fraud settlement was the largest in state history and that the company's subsidiary, CRC Health, billed Medicaid for $8.5 million in elevated costs for blood and urine tests that weren’t performed at its drug treatment centers.
Rates of heart failure—related deaths among individuals 35 to 64 years old are on the rise, according to CNN. The findings appeared in a research paper published in Journal of the American College of Cardiology yesterday. The paper has suggested the cause of rising heart failure deaths could be related to increasing rates of obesity and diabetes.
The FDA has asked sunscreen manufacturers to evaluate the safety of their products’ ingredients after a study by the agency published in JAMA found that several chemicals used in the products may be absorbed into the bloodstream upon use, The Hill reported. FDA researchers found users of sunscreens with the active ingredients ecamsule, octocrylene, avobenzone, or oxybenzone absorbed levels of the chemicals high enough to raise concern for additional safety testing. The levels of the absorbed chemicals in some circumstances were 40 times higher than the levels that would fit under the safety threshold.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Intermountain Healthcare and Story Health Partner to Optimize Rural Heart Failure Care
February 7th 2023On this episode of Managed Care Cast, we speak with Tom Stanis, CEO and cofounder of Story Health, and Phillip Wood, Intermountain Ventures program director, on how their partnership came about, how it is going so far, and the future of their collaboration.
Listen
30-Day Atorvastatin Improved Brachial Artery FMD in Patients With HFpEF, but More Research Is Needed
February 23rd 2024This study was the first of its kind to explore how taking statin medication affects blood vessel function and exercise response in patients with heart failure with preserved ejection fraction (HFpEF), although the cohort only included 16 patients.
Read More
There Is No Interaction Between BMI and SGLT2 Inhibitor Efficacy in HF, Review Finds
February 23rd 2024Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds reduction in all-cause mortality compared with patients taking placebo.
Read More